Qiagen and Epigenomics Collaborate on Colon Cancer Molecular Diagnostics

The test will be based on Epigenomics' proprietary biomarker mSEPT9 and certain DNA methylation analysis technologies.

Epigenomics granted Qiagen a research license to the mSEPT9 biomarker and the technologies. Under this license, Qiagen is currently developing a novel sample-preparation technology that meets the requirements for the future broad implementation of methylation-based molecular diagnostics, such as Septin9-targeted blood testing for the detection of colorectal cancer, on Qiagen's modular molecular testing platform QIAsymphony. Epigenomics will support Qiagen in the R&D phase through knowledge transfer and the collection of clinical specimens as required.

Under the terms of the option agreement, Epigenomics will receive an upfront payment from Qiagen and will be reimbursed for any R&D support and clinical specimens provided during the R&D phase. Upon Qiagen exercising the option, Epigenomics would receive a further license payment. Once Qiagen commercializes a colorectal cancer blood test based on Epigenomics' biomarkers and technology, Epigenomics would be entitled to royalties on Qiagen's net sales as well as certain commercial milestones upon reaching specific revenue targets.

Geert Nygaard, CEO of Epigenomics, commented: "With a clear focus on cancer molecular diagnostics and proven excellence in its fully integrated sample preparation and assay technology platforms for molecular testing, Qiagen is an ideal further partner to give laboratories and thereby physicians and patients broad access to colorectal cancer blood testing as a convenient addition to currently available methods for early detection. This new agreement significantly expands our existing long-lasting and successful partnership with Qiagen, and we are looking forward to moving this project to the next stage."

Related Links:

Qiagen
Epigenomics